Scholar Rock gets first FDA nod for rare muscle-wasting disease - Reuters
Scholar Rock gets first FDA nod for rare muscle-wasting disease Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPVU5NMExYODNrTUtaUGJWeGhmcDI4UmVHaWZEU2M4Tkc5Mkd1MHVSMmJhOXlDeEdQZE1JTW0xa0lyV1A4U2gwMmEzMzl6TW5lb25zaGlWTXAwc3g5S2Q0U2Y0NG01bzk3Z2kyRE5UcENFSmUyVlFwcHo3Y2JYYks0S29nRkpsakIxSDZfdV9xeHJITlVGUkU4cE9IeHpIU2FnOFc2b1p1RUdibS1OakFBMEQ2bUZDakhRQmhXRXJVdw?oc=5" target="_blank">Scholar Rock gets first FDA nod for rare muscle-wasting disease</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
US FDA approves AbbVie's drug for Parkinson's disease - reuters.com
US FDA approves AbbVie's drug for Parkinson's disease reuters.com
September 25, 2026 at 10:57 PMRegeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial - reuters.com
Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial reuters.com
September 30, 2026 at 10:30 PMFDA seeks scientists and consumer representatives for advisory panels - reuters.com
FDA seeks scientists and consumer representatives for advisory panels reuters.com
September 30, 2026 at 08:30 PMUniQure plunges as Huntington's trial data disappoints investors - reuters.com
UniQure plunges as Huntington's trial data disappoints investors reuters.com
September 29, 2026 at 10:11 PMUS FDA extends review of Novo Nordisk's hemophilia drug over facility issues - Reuters
US FDA extends review of Novo Nordisk's hemophilia drug over facility issues Reuters
October 2, 2026 at 09:52 PMLilly's experimental drug cuts weight by 21% in diabetes trial - reuters.com
Lilly's experimental drug cuts weight by 21% in diabetes trial reuters.com
September 29, 2026 at 10:15 PM